An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T Cells

(2015) Shruthi Prasad et al.   CANCER RESEARCH

Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice

(2014) A. Kubler et al.   BLOOD

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

(2014) Julia Steinbacher et al.   INTERNATIONAL JOURNAL OF CANCER

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutrophils mediate antibody-induced antitumor effects in mice

(2013) M. Albanesi et al.   BLOOD

Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo

(2013) Jianhua Huang et al.   CLINICAL IMMUNOLOGY

Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome

(2013) Jeanette Woiterski et al.   INTERNATIONAL JOURNAL OF CANCER

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies

(2013) Ursula J. E. Seidel et al.   Frontiers in Immunology

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges

(2012) Philipp Grosse-Gehling et al.   JOURNAL OF PATHOLOGY

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

(2012) M Hofmann et al.   LEUKEMIA

Human NK receptors: From the molecules to the therapy of high risk leukemias

(2011) Lorenzo Moretta et al.   FEBS LETTERS

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

(2010) H. M. Horton et al.   BLOOD

Rituximab

(2010) Gillian M. Keating   DRUGS

Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation

(2010) Benjamin J. Schmiedel et al.   INTERNATIONAL JOURNAL OF CANCER

Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

(2010) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

(2009) S Giebel et al.   BONE MARROW TRANSPLANTATION

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95

(2008) T. Herrmann et al.   CANCER RESEARCH

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY